Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Gilead Sciences, Inc. GILD

Healthcare  —  Drug Manufacturers General
150.93 1.24 0.83% as of 25 Sep
Market cap
$183.2B
P/E
0.0×
S&P 500 Member Dividend Champion (10y)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Gilead Sciences, Inc. (GILD) EV/Sales

As of 25 September 2026, Gilead Sciences, Inc. (GILD) trades at a EV/Sales of 6.9×. Over the past ten years it has ranged from 3.3× (June 2017) to 7.2× (February 2026); the current reading is higher than 99% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Annual

Period EV/Sales Change
FY2025 5.8× 25.86%
FY2024 4.6× 1.22%
FY2023 4.5× (2.79%)
FY2022 4.7× 13.31%
FY2021 4.1× 3.20%
FY2020 4.0× 6.84%
FY2019 3.7× 3.92%
FY2018 3.6× (11.08%)
FY2017 4.0× 6.96%
FY2016 3.8× (20.99%)

Quarterly

Period EV/Sales Change
Jun 2026 5.9× (6.28%)
Mar 2026 6.3× 9.29%
Dec 2025 5.8× 7.95%
Sep 2025 5.3× (2.15%)
42 more quarters

Against its own ten years

Low 3.3× High 7.2×
Ten-year median 4.2×
Current reading's percentile 99

EV/Sales against peers

Company EV/Sales
SNY Sanofi compare 2.0×
GSK GSK PLC Sponsored ADR compare 2.7×
BMY Bristol Myers Squibb Company compare 3.3×
PFE Pfizer Inc. compare 3.4×
NVO Novo Nordisk A/S compare 3.6×
AZN AstraZeneca PLC compare 4.6×
NVS Novartis AG compare 5.6×
GILD Gilead Sciences, Inc. 6.9×
AMGN Amgen Inc. compare 7.0×
Drug Manufacturers General industry median 4.0×
Healthcare sector median 3.6×
Market median 2.2×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on GILD